ROZALIYA VERNIKOV: Open Payments
NPI 1740362433 · GLEN COVE, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,606 in 160 payments from 11 companies in 2025. Trend: 2023 $3,923 · 2024 $4,357 · 2025 $4,606
Food & beverage: $4,606
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 24 | $762 |
| Axsome Therapeutics, Inc. | 20 | $731 |
| Alkermes, Inc. | 14 | $571 |
| Teva Pharmaceuticals USA, Inc. | 25 | $569 |
| Lundbeck LLC | 21 | $431 |
| Otsuka America Pharmaceutical, Inc. | 12 | $391 |
| Vanda Pharmaceuticals Inc. | 14 | $389 |
| E.R. Squibb & Sons, L.L.C. | 13 | $301 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $219 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $192 |
Products named: INGREZZA, Auvelity, REXULTI, AUSTEDO XR, ARISTADA, COBENFY, LYBALVI, CAPLYTA.
Industry payments across NY — which companies pay providers there.
